For instance, patients in group 1, characterized by the lowest immune response, lowest expression levels of all seven immune checkpoint molecules, highest tumor purity and poor prognoses, may benefit from a combination therapy of enhanced immunity and targeted tumor cell, while patients in group 2, characterized by medium immune activation, relatively high immune suppression, relatively high expression levels of immune checkpoint molecules of CTLA-4 and LAG-3 and poor prognoses, may benefit from a combination therapy of enhanced immunity and immune checkpoint inhibitors. The gene discussed is LAG3; the disease is neoplasm.